Company intelligence / Profile preview
Taejoon Pharmaceutical Co., Ltd.
- Ownership
- Private
- Employees
- ~51
- Development stage
- Commercial
Overview
Taejoon has multiple commercialized products in ophthalmology and radiology globally. Their R&D pipeline includes preclinical to Phase 3 assets targeting eye and GI diseases. Notably, their anti-VEGFR2 antibody program aims to address unmet needs in wet AMD patients unresponsive to current anti-VEGF therapies. They are also active in developing improved formulations and new indications for existing drugs[1][5][8].
- Therapeutic areas
- OtherOphthalmologyGastroenterology
- Modalities
- Small moleculesmonoclonal antibodiesmolecular gluescontrast agents[5][10]
- Industry
- Biotech
Drug pipeline
20 assets19 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Taejoon Pharmaceutical Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Taejoon Pharmaceutical Co., Ltd..